Metrics in Balance N.V. Overview
| Field | Detail | Source |
|---|---|---|
| Legal name | Metrics in Balance NV (Naamloze Vennootschap; French: SA) | NBB FY2024 filing |
| Former names | None identified | NBB filings; KBO extract referenced on IR site |
| Founding / incorporation | Directors' mandates start 25 Oct 2016. Crossroads Bank for Enterprises (KBO) start date 28 Oct 2016. Some aggregators cite a deed publication of 3 Nov 2016. | NBB FY2022/FY2024 filings; Companyweb; Staatsbladmonitor |
| Founders | Guy De Vreese, Marc Gryspeerdt, Philippe Van Acker | TradingView company profile |
| Incorporation jurisdiction | Belgium. Register of Legal Entities (RPR) at the Enterprise Court of Ghent, Ghent division. | NBB FY2024 filing |
| Enterprise / VAT number | 0665.584.108 / BE0665.584.108 | NBB FY2024 filing |
| LEI | 9676001O8J81JR4HH394 | IR website |
| Registered office / HQ | Zuiderlaan 1-3, box 8, 9000 Gent, Belgium. Shared with Remedent NV. Some aggregators list Melle, BE, which conflicts with the filings. | NBB FY2024 filing; IR website; TickerSpark |
| Exchange / market | Euronext Access Paris (MTF, not a regulated market) | Euronext listing showcase; IR website |
| Ticker | MLMIB (MLMIB.PA) | Euronext; IR website |
| ISIN | BE0974328602 | Euronext; IR website |
| CUSIP | Not applicable / not publicly disclosed | — |
| FIGI | BBG00KB6ZGH7 | sustainabilityreports.com |
| PEA / PEA-PME eligibility | Yes / Yes (per French broker data) | Easybourse |
| Listing date | 15 March 2018 per IR website. The Euronext showcase records the operation date as 20 March 2018. | IR website; Euronext |
| Listing method / price | Technical admission (private-placement category), 2,050,000 shares at EUR 5.65, valuation EUR 11.6m | Listing press release, 16 Mar 2018 |
| Listing sponsor (2018) | Genesta (Hervé Guyot) | Listing press release, 16 Mar 2018 |
| Fiscal year end | 31 December | NBB filings |
| Shares outstanding | 4,390,543 registered shares per NBB FY2022/FY2024 filings. The IR website says 4,390,523; Easybourse says 4,390,520. | NBB; IR website; Easybourse |
| Share capital | EUR 12,438,001 (IR site: EUR 12,438,001.27) | NBB FY2024 filing; IR website |
| Employees (parent) | 0 FTE (FY2024). No staff costs booked in FY2021–FY2024. Historic: c.1.8–2 employees in FY2018–FY2019. | Companyweb; NBB filings; FinCheck |
| Employees (group) | — | — |
| Auditor | None. | NBB FY2022 and FY2024 filings |
| Market capitalisation | c. EUR 144.9k at the last available quote of EUR 0.033/share | Simply Wall St (accessed Oct 2026) |
| Website | www.metricsinbalance.com | IR website |
| Principal activity code (Belgium) | Rental and leasing of medical and paramedical equipment (Companyweb). Specialised retail of medical and orthopaedic goods (FinCheck). | Companyweb; FinCheck |
The entity profiled is the one on the identification list. No name change or listing transfer has been identified. The ticker, ISIN, website and Belgian domicile all match.
| Metric | FY2018 | FY2019 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
| Employees, parent entity (headcount/FTE) | 2 | 2 | — | — | 0 |
| Staff costs, parent entity (EUR) | — | — | 0 | 0 | 0 |
Sources: FinCheck (FY2018–FY2019); NBB filings (FY2022–FY2024 staff-cost line empty); Companyweb (FY2024 0 FTE).
Metrics in Balance N.V. is a Ghent-based micro-cap holding company. It began as a dental-occlusion diagnostics and custom-splint concept and has since become a small operator of musculoskeletal clinics in the Netherlands. Its founding thesis was that a bad bite can disturb posture and cause pain elsewhere in the body. It combined third-party measurement devices (an intra-oral 3D scanner, a jaw-motion recorder, a 4D spine scanner and a foot-pressure scanner) into a branded diagnostic protocol, followed by custom splint therapy. From 2020 the operating focus moved to chiropractic and physiotherapy clinics under the Dutch "Balans" brand, run through a wholly owned Dutch subsidiary. A DNA-based lifestyle-testing venture ("DNA Talks") followed in 2022. The listed parent has negligible turnover, no employees, a going-concern caveat and a balance sheet dominated by an unimpaired EUR 12.26m subsidiary carrying value. Its market capitalisation is below EUR 0.2m, making it effectively an illiquid shell-like listing over a small private clinic business.
What the company does
MiB describes itself on its corporate website as a holding company with three positions:
-
Balans healthcare clinics. These are multi-disciplinary chiropractic and physiotherapy clinics in the Netherlands, run through Metrics in Balance Nederland B.V. In mid-2022 the website said the group owned and operated six clinics, in Eindhoven, Malden, Tilburg (two), Venlo and Horst. Venlo and Horst were acquired at the end of June 2022. A greenfield clinic in Rotterdam was planned for September 2022. The stated model was buy-and-build, targeting 20 clinics within 36 months and then other countries.
-
DNA Talks: lifestyle testing. This is a B2B2C model in which DNA-based lifestyle tests are sold through distributors and independent coaches. Gut-microbiome, blood-analysis and stress tests were described as "coming soon". DNA Talks was incorporated in Belgium in April 2022, and DNA Talks AG followed in Switzerland at the end of June 2022.
-
Occluso-posture therapy. This is the original MiB concept: measure occlusion and posture, then correct with custom splints. The website describes it as "being tested at the moment".
Source: metricsinbalance.com/company. The page content dates from mid-2022 and has not visibly been updated.
The Company's own description (statutory management report, FY2024)
The board's FY2024 report to the 14 July 2025 AGM gives the following picture (paraphrased from Dutch):
-
During FY2024 the company focused further on the Dutch market. Its emphasis moved towards building out the "Balans" centres, meaning chiropractic and physiotherapy practices.
-
MiB describes itself as a company that performs body measurements starting at the teeth and ending at the feet, which allow a person's posture to be mapped.
-
The commercial focus was the treatment of mechanical back complaints in "Balans rug centra" (back centres), grounded in measurements from the MiB system.
-
Since the balance-sheet date, progress in the Netherlands has continued but has been slower than planned.
-
The company is working on diversification and on tapping an alternative segment.
-
R&D activity was minimal.
Original concept (2018 listing document)
The March 2018 listing press release framed MiB as a measurement-diagnosis-remediation concept for malocclusion. It measures without pain or radiation:
-
the teeth;
-
temporomandibular joint (TMJ) motion and its actual versus ideal position;
-
the spinal column;
-
foot pressure and balance.
The devices named were a Condor intra-oral 3D scanner, a Freecorder, a Diers 4D spine scanner and a pedoscan. The release claimed that roughly 10–20% of posture problems are "ascending" (starting below) and 80–90% "descending" (starting above).
The core monetisable product was custom dental splints: sports splints, protection splints, anti-stress splints and anti-bruxism splints. The stated ambition was to become the world's leading splint company.
MarketScreener and Easybourse summarise the original model as three revenue streams:
-
sale of the medical devices associated with the concept;
-
royalties from practices using the "Metrics in Balance" brand;
-
production and distribution of custom dental splints.
Business and revenue model
| Revenue stream | Mechanism | Entity | Status (latest evidence) |
|---|---|---|---|
| Clinic patient fees (chiropractic, physiotherapy) | Fee-for-service. Dutch physiotherapy is partly reimbursed through supplementary insurance contracts. | Metrics in Balance Nederland B.V. and/or clinic entities | Operating. "Balans Fysio BV", Boschdijk 391, Eindhoven (balans-rugcentrum.nl email domain), is listed by insurer Zilveren Kruis as contracted for physiotherapy through 2027. Its legal link to MiB is not confirmed in filings. |
| Ancillary products (insoles, posture wearables, supplements, mattresses) | Product resale within clinics | Clinic entities | Described in the July 2020 press release; revenue not disclosed |
| Device sales / brand royalties | Equipment sale or lease plus royalty from licensed practices | Parent (historic) | Parent turnover of EUR 300 in FY2022 and FY2023 indicates this stream is dormant |
| Custom splints | Product manufacture and sale | Parent (historic) | Concept "being tested" (2022). No disclosed revenue. |
| DNA lifestyle tests | B2B2C via coaches and distributors | DNA Talks BV (BE); DNA Talks AG (CH) | 25 active coaches in NL and a France distribution contract signed (mid-2022). DNA Talks BV equity was negative at EUR -165,011 at end-FY2024. |
| Intercompany services | Recharges to subsidiaries | Parent | Receivables from affiliates of EUR 90,126 (FY2024). Parent FY2024 turnover of EUR 30,100 is consistent with a one-off goods sale (purchases of EUR 30,000 in the same year). |
Mix: The product / service / subscription / licensing split is not publicly disclosed at group level. At parent level, revenue is de minimis and irregular.
Value-chain position, customers and end-markets
| Dimension | Characterisation |
|---|---|
| Customer types | Patients with chronic back, neck and posture-related pain (B2C). Historically, dental and allied-health practitioners licensing the concept (B2B). Lifestyle coaches and distributors for DNA tests (B2B2C). |
| End-markets | Dutch chiropractic and physiotherapy; European consumer lifestyle and genetic testing; dental occlusion and TMJ-disorder therapy (dormant) |
| Geography | Operations in the Netherlands; holding in Belgium; a DNA Talks entity in Switzerland; a DNA Talks distribution agreement with France (2022) |
MiB sits at the downstream, patient-facing end of the musculoskeletal-care value chain. It does not manufacture the diagnostic hardware, which comes from third parties (Condor, Diers and others). It integrates these devices into a branded protocol and monetises through clinic services and, in principle, splints and test kits.
Independent characterisation
On the evidence available, MiB is best understood as a listed holding shell over a small, loss-making private clinic subsidiary.
-
The listed parent's statutory accounts show EUR 300 of turnover in each of FY2022 and FY2023, and EUR 30,100 in FY2024.
-
Its EUR 12.26m of assets are almost entirely the carrying value of two 100% subsidiaries. Both report negative equity: Metrics in Balance Nederland B.V. at EUR -316,735 and DNA Talks BV at EUR -165,011, both at 31 Dec 2024.
-
No impairment has been booked.
-
The share has traded at EUR 0.03 with no reported movement over the past year (Simply Wall St).
-
The company's own website has not updated its press-release list since July 2020 or its business description since mid-2022.
The diagnostic concept is intellectually distinctive. However, it relies on contested clinical claims linking dental occlusion to whole-body posture, and it has not demonstrated commercial traction at the listed-entity level.
Strategy
Stated strategy themes
Across its disclosures, MiB has articulated four consistent themes (paraphrased):
-
Root-cause, measurement-led care. Find the origin of chronic pain through objective scanning rather than treating symptoms (2018 listing release; 2020 release).
-
From "sick-care" to "prevention-care". A multidisciplinary, patient-centric, holistic model, with the company presenting itself as an early mover (2020 release).
-
Buy-and-build in Dutch musculoskeletal care. Acquire and open "Balans" clinics; targets have been 30 locations (2020) and then 20 clinics within 36 months, followed by other countries (2022 website).
-
Diversification. Add revenue streams such as DNA Talks lifestyle testing, and pursue an "alternative segment" (FY2022 and FY2024 board reports).
Initiatives in the last 24 months (Oct 2024 – Oct 2026)
| Initiative | Detail | Status | Source |
|---|---|---|---|
| Refinancing / new capital | The board states it is working on "important additional financing / refinancing" and that talks on financing and/or capital increases are pending | Ongoing as of the 14 Jul 2025 AGM; no completion announced | NBB FY2024 report |
| Cost containment and internal reorganisation | Planned investments slowed and an internal reorganisation carried out to limit losses | Implemented | NBB FY2024 valuation-rules note |
| Diversification into an "alternative segment" | Not specified; market research began around end-May 2023 (FY2022 report) | No outcome disclosed | NBB FY2022 and FY2024 reports |
| Continued Balans roll-out in the Netherlands | Back-centre build-out, slower than planned | Ongoing | NBB FY2024 report |
Older initiatives (2020–2022): Balans rebrand and the Tilburg greenfield (2020); Venlo and Horst acquisitions and a planned Rotterdam greenfield (2022); DNA Talks launch (BE April 2022, CH June 2022) with a France distribution contract and a target of one distributor per European country.
ESG commitments, cost programmes and medium-term targets
ESG / sustainability commitments: none disclosed.
Cost programme targets: none quantified.
Medium-term financial guidance: none issued. The only quantified targets have been operational: 4 owned locations by end-2020 and at least 30 overall (2020); 20 clinics within 36 months (2022); 250 NL coaches and 2,000 French coaches for DNA Talks (2022). None has been reported as achieved; the latest disclosed network size is 6 clinics (mid-2022).
Products & Services
Balans healthcare clinics (Netherlands)
| Offering | Description | Target customer | Launch / latest | Pricing | Source |
|---|---|---|---|---|---|
| Balans Rugcentrum: chiropractic care | Chiropractic treatment of mechanical back and neck complaints, guided by scan-based diagnosis of the "root cause" | Adults with chronic back/neck pain | Eindhoven centre acquired 2020; brand in place since 2020 | — | Press release 2 Jul 2020; website |
| Physiotherapy (Balans Fysio) | Physiotherapy, manual therapy and oedema therapy (Eindhoven). Contracted by Zilveren Kruis through 2027. | Insured patients | Ongoing | Insurer-contracted tariffs (not disclosed) | Zilveren Kruis directory |
| Scan-based diagnostics | Advanced scanning to "pinpoint" pain origin before treatment | Clinic patients | 2,020 | — | Press release 2 Jul 2020 |
| Aftercare and maintenance programmes | Exercise plans, dietary supplements, mechanical supports (insoles, posture wearables, mattresses) | Discharged patients | 2,020 | — | Press release 2 Jul 2020 |
| Clinic locations | Eindhoven, Malden, Tilburg (2), Venlo, Horst; Rotterdam planned (Sep 2022) | — | Mid-2022 snapshot | — | Company website |
Throughput claim: The two 2020 locations would serve more than 400 patients per week (press release, July 2020). No later throughput data has been disclosed.
DNA Talks: lifestyle testing
| Offering | Description | Channel | Status | Source |
|---|---|---|---|---|
| DNA lifestyle test | Genetic test for lifestyle guidance | Coaches and distributors (B2B2C) | 25 active coaches in NL (target 250). France distribution contract signed (target 2,000 coaches). Goal of one distributor in each of 26 European countries. | Company website (mid-2022) |
| Gut microbiome test | Planned | Same | "Coming soon" (2022). Launch not confirmed. | Company website |
| Blood analysis | Planned | Same | "Coming soon" (2022). Launch not confirmed. | Company website |
| Stress test | Planned | Same | "Coming soon" (2022). Launch not confirmed. | Company website |
| Customer software platform and webshop | Proprietary customer platform; new website/webshop | Online | Expected live mid-July 2022. Current status not disclosed. | Company website |
Occluso-posture therapy (original MiB concept)
| Offering | Description / specifications | Target | Year | Pricing | Source |
|---|---|---|---|---|---|
| MiB measurement protocol | Radiation-free, painless measurement of teeth, TMJ motion and position, spine and foot pressure | Dentists, chiropractors, physiotherapists, osteopaths and their patients | 2016–2018 | Device sale plus brand royalty (amounts not disclosed) | Listing press release 2018; MarketScreener |
| Condor intra-oral 3D scanner (third-party) | Intra-oral optical scanning of the dentition. Condor Technologies NV is linked to Guy De Vreese, who is its managing director. | Practitioners | 2,018 | — | Listing press release; MarketScreener insider profile |
| Freecorder (third-party) | Jaw-motion / TMJ recording | Practitioners | 2,018 | — | Listing press release |
| Diers 4D spine scanner (third-party) | Optical back-surface and spine analysis | Practitioners | 2,018 | — | Listing press release |
| Pedoscan (third-party) | Plantar pressure and balance | Practitioners | 2,018 | — | Listing press release |
| MiB custom splints | Individually made splints in various compounds, colours and thicknesses. Marketed with a claim of perfect fit and higher compliance. | Patients with malocclusion; athletes | 2,018 | — | Listing press release |
| Sports splints | Performance and injury-prevention splint | Athletes | 2,018 | — | Listing press release |
| Protection splints | Dental protection | Patients | 2,018 | — | Listing press release |
| Anti-stress splints | Stress-related clenching | Patients | 2,018 | — | Listing press release |
| Anti-bruxism splints | Grinding prevention | Patients | 2,018 | — | Listing press release |
| Concept status | "Being tested at the moment" | — | Mid-2022 | — | Company website |
Financial Narrative
Basis of preparation. All figures are from the non-consolidated statutory accounts of Metrics in Balance NV (parent only) under Belgian GAAP (full "VOL" schema). They were filed with the NBB and approved by the AGMs of 28 Aug 2023 (FY2022) and 14 Jul 2025 (FY2024). FY2020 values come from aggregators summarising the NBB filing (Staatsbladmonitor) because the FY2020 PDF on the IR site is not machine-readable. FY2025 draft statements are posted but are likewise not machine-readable and are treated as not publicly disclosed.
No cash-flow statement is filed: Belgian GAAP does not require one for this entity. These are not group figures. The loss-making clinic operations are excluded.
Income statement (EUR)
Sources: NBB FY2022 filing (FY2022 and FY2021 columns); NBB FY2024 filing (FY2024 and FY2023 columns). EBITDA and EPS are derived. The Belgian "brutomarge" (turnover plus other operating income minus goods minus services) matches Companyweb's "gross margin" series exactly. Simply Wall St presents FY2024 as revenue 30.1k, cost of revenue 49.8k and gross profit -19.7k, a different cost allocation.
Margins and growth (%)
Derived from NBB filings. Margins on such a small and erratic revenue base carry little economic meaning; they are shown for completeness. The FY2021 and FY2024 positive results depend on non-recurring income: a EUR 64,626 gain on disposal of tangible assets in FY2021 and EUR 38,152 of other non-recurring operating income in FY2024.
Revenue CAGR FY2021–FY2024: approx. -18.2% per year (EUR 55,024 to EUR 30,100), derived. A five-year CAGR cannot be computed because FY2020 turnover is not publicly disclosed in the sources reviewed.
Longer history (EUR)
The two aggregators differ by EUR 1.2k–3.0k per year on net result, possibly reflecting pre- versus post-allocation figures. Both are shown.
Balance sheet (EUR, 31 December)
Sources: NBB FY2022 and FY2024 filings; Staatsbladmonitor (FY2020 equity and debts); FY2020 retained losses derived from the FY2021 filing. Net financial debt is derived as financial debt (long-term, current portion and short-term) minus cash. "Other short-term debts" of EUR 684,299 at end-FY2024 are not itemised. Their nature is not publicly disclosed; they may include shareholder or related-party current accounts or the 2020 crowdlending notes.
Cash flow (EUR)
No cash-flow statement is filed. Capex is taken from the tangible fixed-asset movement schedule: a EUR 30,000 asset under construction was acquired in FY2022 and disposed of in FY2024. Change in cash is derived from balance-sheet cash.
Ratios
All derived from NBB filings. Where both years were available, averages use opening and closing balances; FY2021 averages use the FY2020 equity of 11,798,460 and FY2020 total assets of 12,275,294 (derived as equity plus liabilities). TickerSpark's ROE of -0.45% and ROIC of -0.39% agree with the FY2022 derivations. The cash conversion cycle is not computable because cost of sales is negligible and volatile, so it is not meaningful.
Commentary on trends, inflections and drivers
Revenue. The parent's turnover has never exceeded EUR 56k. In FY2017 and FY2021, revenue of about EUR 55k probably reflected device or equipment sales or recharges. FY2022 and FY2023 revenue of EUR 300 per year is consistent with a dormant holding. The FY2024 rebound to EUR 30,100 coincides with EUR 30,000 of goods purchases, pointing to a single pass-through sale at a small loss. The board itself attributes the near-absence of sales to a "reorganisation phase" and the focus on the Dutch market (FY2024 valuation-rules note, continuity section).
Profitability. Underlying operating costs (services plus goods, excluding pass-throughs) fell from about EUR 92k in FY2021 to about EUR 16k in FY2024. This reflects cost control at holding level. Reported profits in FY2021 and FY2024 depend entirely on non-recurring income. Excluding it, underlying EBITDA has been negative every year: EUR -37k, -40k, -33k and -19k.
Balance sheet quality. Total assets of EUR 12.6m are 97% a single line: participations in subsidiaries at an unchanged historical cost of EUR 12,261,250. That cost originates in the March 2019 contribution in kind. Both subsidiaries report negative equity at end-FY2024 (combined EUR -481,746). No write-down has been booked, and the valuation rules for financial fixed assets mention only cash deposits, not impairment testing. On a look-through basis, the reported equity of EUR 11.7m is not supported by the subsidiaries' net assets. Any value must rest on future earnings of the clinics, for which no disclosure exists. The absence of an auditor heightens this concern.
Liquidity and leverage. Reported financial leverage is negligible relative to book equity, but this is misleading. Measured against liquid assets, the parent is illiquid:
-
cash was zero at end-FY2024;
-
working capital was EUR -447k;
-
current ratio 0.44x;
-
"other short-term debts" have risen steadily to EUR 684k;
-
interest costs have doubled since FY2022 to EUR 15.2k.
The board has flagged pressure on operating cash flow and an ongoing search for "important additional financing / refinancing" in both the FY2022 and FY2024 reports.
Inflections.
FY2019: recapitalisation: equity moved from EUR -0.37m to EUR +11.8m.
FY2022: bank borrowing: c. EUR 194k from credit institutions, coinciding with the Venlo and Horst acquisitions.
FY2024: marginal return to profit, on non-recurring items only.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Group Entities
| Entity | Jurisdiction / ID | Ownership | Role | Equity at last report (EUR) | Net result at last report (EUR) | Source |
|---|---|---|---|---|---|---|
Metrics in Balance NV | Belgium, 0665.584.108 | Listed parent; Remedent NV c.28.47% (Sep 2020) | Holding; historic device/splint concept | 11,706,308 (FY2024) | 9,069 (FY2024) | NBB FY2024 |
Metrics in Balance Nederland B.V. | Netherlands, KvK 70461139, Dr Cuyperslaan 74, 5623 BB Eindhoven | 100% | Operates the Balans clinics | -316,735 (FY2024) | -183,586 (FY2024) | NBB FY2024 participations note |
DNA Talks BV | Belgium, 0694.872.960, Zuiderlaan 1-3/8, Gent | 100% (2,000 shares) | DNA lifestyle testing | -165,011 (FY2024) | 404 (FY2024) | NBB FY2024 participations note |
DNA Talks AG | Switzerland | Not disclosed in parent filing (may be held by DNA Talks BV or third parties) | Distributor and coach recruitment vehicle | — | — | Company website |
Balans Fysio BV (Eindhoven) | Netherlands | Relationship to MiB not confirmed | Physiotherapy practice using the balans-rugcentrum.nl domain | — | — | Zilveren Kruis provider directory |
“—” = not publicly disclosed.
Segment (proxy) — revenue (EUR)
| Segment (proxy) — revenue (EUR) | FY2022 | FY2023 | FY2024 |
|---|---|---|---|
Parent-company statutory turnover (EUR) | 300 | 300 | 30,100 |
Revenue by Segment (EUR)
| Subsidiary — net result (EUR) | FY2022 | FY2024 |
|---|---|---|
Metrics in Balance Nederland B.V. net result (EUR) | -168,959 | -183,586 |
DNA Talks BV net result (EUR) | -70,005 | 404 |
Subsidiary — equity (EUR)
| Subsidiary — equity (EUR) | FY2022 | FY2024 |
|---|---|---|
Metrics in Balance Nederland B.V. equity (EUR) | -84,944 | -316,735 |
DNA Talks BV equity (EUR) | -105,682 | -165,011 |
Income Statement (EUR) and Per-Share Data
| Metric | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
Turnover (EUR) | — | 55,024 | 300 | 300 | 30,100 |
Other operating income (EUR) | — | 77 | 16,952 | 58 | 1,406 |
Non-recurring operating income (EUR) | — | 64,626 | 0 | 0 | 38,152 |
Total operating income (EUR) | — | 119,727 | 17,252 | 358 | 69,658 |
Goods for resale, net of stock change (EUR) | — | 33,721 | 673 | 200 | 32,433 |
Services and other goods (EUR) | — | 58,308 | 51,578 | 33,084 | 13,390 |
Staff costs (EUR) | — | 0 | 0 | 0 | 0 |
Depreciation and amortisation (EUR) | — | 20,073 | 6,666 | 2,150 | 246 |
Inventory write-downs (EUR) | — | 0 | 4,500 | 0 | 4,021 |
Other operating costs (EUR) | — | 120 | 122 | 132 | 391 |
Gross profit: turnover minus goods (EUR) | — | 21,303 | -373 | 100 | -2,333 |
Gross margin, Belgian "brutomarge" definition (EUR) | — | -36,928 | -34,999 | -32,926 | -14,316 |
Operating result / EBIT (EUR) | — | 7,505 | -46,287 | -35,208 | 19,178 |
EBITDA: EBIT plus D&A (EUR) | — | 27,578 | -39,621 | -33,058 | 19,424 |
Underlying EBITDA excluding non-recurring income (EUR) | — | -37,048 | -39,621 | -33,058 | -18,728 |
Financial income (EUR) | — | 1,000 | 1,609 | 0 | 5,467 |
Financial costs (EUR) | — | 5,911 | 8,781 | 15,148 | 15,576 |
of which interest on debt (EUR) | — | 3,026 | 7,093 | 14,135 | 15,205 |
Pre-tax result (EUR) | — | 2,594 | -53,459 | -50,356 | 9,069 |
Income tax (EUR) | — | 0 | 0 | 0 | 0 |
Net result (EUR) | — | 2,594 | -53,459 | -50,356 | 9,069 |
EPS basic = diluted, on 4390543 shares (EUR) | — | 0.0006 | -0.0122 | -0.0115 | 0.0021 |
Dividend per share (EUR) | 0 | 0 | 0 | 0 | 0 |
Margin Analysis (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|
Operating margin on turnover (%) | 13.6 | -15,429.0 | -11,736.0 | 63.7 |
EBITDA margin on turnover (%) | 50.1 | -13,207.0 | -11,019.3 | 64.5 |
Net margin on turnover (%) | 4.7 | -17,819.7 | -16,785.3 | 30.1 |
Turnover growth YoY (%) | — | -99.5 | 0.0 | 9,933.3 |
Balance Sheet (EUR)
| Metric | FY2017 | FY2018 | FY2019 |
|---|---|---|---|
Turnover (EUR) | 56,145 | 1,349 | 32,727 |
Net result, Staatsbladmonitor (EUR) | -230,561 | -297,759 | -105,016 |
Net result, FinCheck (EUR) | -231,755 | -300,667 | -107,990 |
Equity (EUR) | -170,255 | -370,922 | 11,797,589 |
Total debts (EUR) | 248,189 | 453,730 | 429,667 |
Balance Sheet (EUR) (FY2020–FY2024)
| Metric | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
Formation expenses (EUR) | — | 8,627 | 2,189 | 166 | 0 |
Tangible fixed assets (EUR) | — | 435 | 30,207 | 30,080 | 0 |
Financial fixed assets: subsidiaries (EUR) | — | 12,261,250 | 12,261,250 | 12,261,250 | 12,261,250 |
Inventories (EUR) | — | 18,215 | 14,974 | 14,974 | 8,521 |
Trade receivables (EUR) | — | 137,065 | 267,495 | 233,176 | 181,385 |
Other receivables (EUR) | — | 5,073 | 6,686 | 3,008 | 165,729 |
Cash and equivalents (EUR) | — | 1,825 | 481 | 90 | 0 |
Total current assets (EUR) | — | 162,179 | 289,636 | 251,248 | 355,635 |
Total assets (EUR) | — | 12,432,490 | 12,583,281 | 12,542,744 | 12,616,885 |
Share capital (EUR) | 12,438,001 | 12,438,001 | 12,438,001 | 12,438,001 | 12,438,001 |
Retained losses (EUR) | -639,541 | -636,947 | -690,406 | -740,763 | -731,694 |
Total equity (EUR) | 11,798,460 | 11,801,054 | 11,747,595 | 11,697,239 | 11,706,308 |
Long-term financial debt (EUR) | — | 0 | 197,190 | 161,180 | 82,682 |
of which credit institutions (EUR) | — | 0 | 155,875 | 116,864 | 35,367 |
of which other loans (EUR) | — | 0 | 41,315 | 44,315 | 47,315 |
Current portion of long-term debt (EUR) | — | 0 | 37,915 | 40,325 | 41,335 |
Short-term financial debt (EUR) | — | 100,000 | 0 | 0 | 2 |
Trade payables (EUR) | — | 121,521 | 127,328 | 134,442 | 77,451 |
Other short-term debts (EUR) | — | 372,150 | 449,804 | 486,188 | 684,299 |
Accruals (EUR) | — | 37,765 | 23,450 | 23,370 | 24,806 |
Total liabilities (EUR) | 476,834 | 631,436 | 835,686 | 845,505 | 910,577 |
Total financial debt (EUR) | — | 100,000 | 235,105 | 201,505 | 124,019 |
Net financial debt (EUR) | — | 98,175 | 234,624 | 201,415 | 124,019 |
Goodwill and intangibles (EUR) | — | 0 | 0 | 0 | 0 |
Working capital: current assets minus short-term debts (EUR) | — | -431,492 | -325,410 | -409,708 | -447,453 |
Receivables from affiliated companies (EUR) | — | 73,247 | 94,597 | 103,015 | 90,126 |
Tax losses carried forward, unrecognised (EUR) | — | — | 680,000 | — | 718,000 |
Cash Flow (EUR)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|
Capex: acquisitions of tangible assets (EUR) | 0 | 30,000 | 0 | 0 |
Dividends paid (EUR) | 0 | 0 | 0 | 0 |
Share buybacks (EUR) | 0 | 0 | 0 | 0 |
Change in cash (EUR) | — | -1,344 | -391 | -90 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|
ROE on average equity (%) | 0.02 | -0.45 | -0.43 | 0.08 |
ROA on average assets (%) | 0.02 | -0.43 | -0.40 | 0.07 |
ROIC: EBIT over equity plus financial debt (%) | 0.06 | -0.39 | -0.30 | 0.16 |
Current ratio (x) | 0.27 | 0.47 | 0.38 | 0.44 |
Financial debt to equity (x) | 0.008 | 0.020 | 0.017 | 0.011 |
Total liabilities to equity (x) | 0.054 | 0.071 | 0.072 | 0.078 |
Net debt to EBITDA (x) | 3.56 | -5.92 | -6.09 | 6.39 |
Interest coverage: EBIT over interest (x) | 2.48 | -6.53 | -2.49 | 1.26 |
Asset turnover (x) | 0.0044 | 0.0000 | 0.0000 | 0.0024 |
Region — revenue (EUR)
| Region — revenue (EUR) | FY2022 | FY2023 | FY2024 |
|---|---|---|---|
Belgium (parent turnover) (EUR) | 300 | 300 | 30,100 |
Valuation Snapshot
| Metric | Value | Source |
|---|---|---|
Last available price | EUR 0.033 | Simply Wall St |
Market cap | c. EUR 144.9k | Simply Wall St |
1-year change | 0% | Simply Wall St |
3-year change | -89.0% | Simply Wall St |
5-year change | -98.9% | Simply Wall St |
Since listing (EUR 5.65) | -99.4% | Simply Wall St |
52-week range | Reported as USD 0.03–0.12 by TickerSpark; Simply Wall St shows no range | TickerSpark; Simply Wall St |
Beta | 0.37–0.42 (aggregators; not meaningful given no trading) | TickerSpark; Simply Wall St |
Average volume | 0 | TickerSpark |
Price reference — EUR per share | FY2018 | FY2019 |
Reference trade or quote (EUR) | 5.65 | 6.99 |
Valuation Multiples
| Multiple | MiB | Comment |
|---|---|---|
P/E | c. 16.0x | Simply Wall St. Based on EUR 9,069 of non-recurring-driven profit; not meaningful. |
EV/EBITDA | c. 13.8x | Derived: EV of 144.9k + 124.0k net financial debt = EUR 268.9k, over EBITDA of EUR 19,424. Not meaningful. |
EV/Sales | c. 8.9x | Derived (268.9k / 30.1k). Not meaningful. |
P/B | c. 0.012x | Derived (144.9k / 11.71m). Reflects market scepticism over the participation's carrying value. |
Peer comparison | Simply Wall St peer average P/E 20.2x (European medical equipment); no meaningful listed peers | Simply Wall St |
Capital Markets
| Item | Status |
|---|---|
Analyst coverage / consensus | None. Simply Wall St reports 0 analysts. |
Dividend history and policy | No dividend ever paid; no policy disclosed |
Buyback authorisations | None disclosed; no treasury shares (NBB) |
Warrants / options | None outstanding (IR website; NBB capital note) |
Credit ratings (Moody's / S&P / Fitch) | Not rated |
Bonds | None listed. A 2020 crowdlending raise of EUR 300k occurred; its residual balance and location (parent or subsidiary) are not disclosed. |
Bucket Details
| Bucket | Credit institutions (EUR) | Other loans (EUR) | Total (EUR) |
|---|---|---|---|
Within 1 year (current portion) | 41,335 | 0 | 41,335 |
1–5 years | 35,367 | 0 | 35,367 |
Over 5 years | 0 | 47,315 | 47,315 |
Total | 76,702 | 47,315 | 124,017 |
Analyst Conclusions
Management guidance
No quantitative guidance has been issued. The FY2024 board report (July 2025) says management will continue building the business through diversification and an alternative segment in order to gradually achieve better results. It also states that progress in the Netherlands is slower than planned and that significant financing or refinancing is being pursued.
Consensus
None. There is no analyst coverage.
Bull case
-
Hidden operating value. The Balans clinic network (six sites in 2022, insurer-contracted physiotherapy through 2027) may carry real operating value that the parent-only accounts do not capture. A market cap of EUR 0.14m against an operating clinic group could re-rate sharply on any credible consolidated disclosure.
-
Refinancing as a catalyst. A successful capital increase or third-party partner, which the board says is under discussion, could fund the buy-and-build in a fragmented Dutch market and use EUR 718k of tax losses.
-
DNA Talks optionality. DNA Talks BV reached break-even in FY2024 (EUR +404) after a EUR -70k loss in FY2022. A scalable coach channel with a signed France distributor offers asymmetric upside at negligible valuation.
Bear case
-
Reported equity overstates value. Equity of EUR 11.7m rests on an unimpaired EUR 12.26m participation in subsidiaries whose combined equity is EUR -0.48m. An impairment would leave the parent with roughly EUR -0.55m of equity (derived: 11,706,308 − 12,261,250).
-
Liquidity is exhausted. Cash is zero, working capital is EUR -447k and short-term other debts have grown every year. The anchor shareholder (Remedent NV) is itself loss-making, with a FY2025 loss of EUR -386k.
-
Governance and disclosure are inadequate. There is no auditor, no independent directors, no communication since 2020 and no trading. Minority shareholders have neither information nor an exit.
Catalysts and monitorables (next 12 months)
| Monitorable | Why it matters |
|---|---|
| Final FY2025 accounts (AGM due by mid-2026; NBB filing) | Confirms whether refinancing closed, whether the subsidiaries were impaired, and the cash position |
| Any capital increase or Belgian Gazette publication | A dilutive rescue or change of control would redefine the equity story |
| Statutory auditor appointment or consolidated accounts | A prerequisite for credibility |
| Clinic network status (count, closures, Rotterdam) | The core operating driver |
| Remedent Inc. / Remedent NV financial health | Capacity of the anchor shareholder to support MiB |
| Euronext Access trading status | Risk of delisting or suspension for lack of activity or disclosure |
| Belgian Code of Companies art. 7:228 "alarm bell" procedure | Triggered if net assets fall below half of capital after an impairment; requires a shareholder meeting on continuity |
Analyst verdict
Metrics in Balance N.V. is, on the public record, a listed holding vehicle in financial distress, whose reported book value cannot be reconciled with its subsidiaries' disclosed results.
The company began in 2016 with an intriguing but scientifically contested premise. It proposed that dental occlusion drives whole-body posture, and that this could be measured with a bundle of third-party scanners and corrected with custom splints. That model never produced material revenue at the listed entity, which earned EUR 300 in each of FY2022 and FY2023. Management then moved to Dutch chiropractic and physiotherapy clinics under the Balans brand and launched a DNA lifestyle-testing side venture. Both sit in subsidiaries that report negative equity: EUR -316,735 for the clinic company and EUR -165,011 for DNA Talks at end-FY2024.
The parent's EUR 11.7m of equity therefore depends on an unimpaired EUR 12.26m carrying value from a 2019 contribution in kind. The market values the whole company at about EUR 0.14m, or about 1% of book, which signals near-total disbelief. The board has warned in successive reports about cash-flow pressure and a need for refinancing. Cash was nil at end-FY2024, and the anchor shareholder is itself shrinking.
Governance compounds the problem. There is no auditor, no independent board member, a dense web of related parties around the chairman's other companies, and no market communication since July 2020.
There is residual optionality. If the Balans clinics are genuinely operating and insurer-contracted, a credible recapitalisation or reverse transaction could reveal value that the parent-only accounts hide, and the tax losses and listing have some shell value. That optionality cannot be assessed without consolidated, audited figures.
Verdict: uninvestable on available information. Treat it as a distressed, illiquid special situation with a high probability of impairment, dilution or delisting. Re-evaluate only on publication of audited consolidated accounts or a disclosed recapitalisation.
Source register
| # | Source | Used for |
|---|---|---|
| 1 | NBB statutory accounts FY2024 (incl. FY2023 comparatives), Metrics in Balance NV, filed 18 Sep 2025 | Financials, board, subsidiaries, debt schedule, management report |
| 2 | NBB statutory accounts FY2022 (incl. FY2021 comparatives), filed 29 Aug 2023 | Financials, board changes, management report |
| 3 | metricsinbalance.com: Investor Relations, Company, Press Releases, Contact pages (accessed Oct 2026) | Listing data, shareholders, structure, business lines |
| 4 | Listing press release, 16 Mar 2018 | Listing terms, original concept, devices, sponsor |
| 5 | Press release, 2 Jul 2020 (also on EIN Presswire, 6 Jul 2020) | Crowdlending, Tilburg, Eindhoven, Balans brand, management bios |
| 6 | Remedent Inc. press release, 29 Apr 2019 (EIN Presswire) | 2019 contribution in kind; share price |
| 7 | Euronext IPO showcase (MLMIB) | Listing date and price |
| 8 | FSMA manager-transaction notifications (2021–2023) | Insider dealings |
| 9 | Simply Wall St; TickerSpark; MarketScreener; TradingView; Easybourse; Financial Modeling Prep | Market data, profiles, insider bios |
| 10 | Companyweb; FinCheck; Staatsbladmonitor; Trends Top; Pappers.be | Historic financials, registration data, Remedent NV figures |
| 11 | Zilveren Kruis provider directory; ZorgkaartNederland; companydata.com; CB Insights | Clinic evidence, competitors |
| 12 | Swissinfo; SRF; Lebensmittelpraxis | Lifestyle genetic-testing market context |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Role | Tenure | Background | Education | Source |
|---|---|---|---|---|---|
Dirk Verstraete | Managing Director (gedelegeerd bestuurder); CEO and Clinical Director | Mandate start 7 Mar 2018 (FY2024 filing); renewed 17 Oct 2022 | Chiropractor with "several decades" of experience; founder of Rug- en Nek Centrum Eindhoven; owner of several businesses | Doctorate, University of California, Los Angeles (per MarketScreener) | NBB filings; press release 2020; MarketScreener |
Guy De Vreese | Managing Director; Chairman and lead investor | Since 25 Oct 2016 (founder); renewed 17 Oct 2022 | Serial dental entrepreneur. Chairman and CEO of Remedent Inc. (since 2008); CEO of Remedent NV (since 2001); managing director of Condor Technologies NV (since 2010); director of Biotech Dental Benelux NV; president of DMDS Ltd. Formerly CEO of Lident NV and DMD NV and co-CEO of Scan4all SAS. | — | NBB filings; MarketScreener |
Cavalli Consulting BV (rep. Marc Gryspeerdt) | Non-executive director | Since 25 Oct 2016 (co-founder); renewed 17 Oct 2022 | Co-founder | — | NBB filings; TradingView |
Philippe Van Acker | Former director | 25 Oct 2016 to 17 Oct 2022 | Co-founder; also listed as a director of Remedent NV | — | NBB FY2022; Pappers.be |
Brecht Hanssens | Investor Relations & Finance (2020) | Current status unknown | — | — | Press release 2020 |
Shane De Vreese | CEO of SmileWise, the incubation partner providing marketing, hiring and fundraising (2020) | — | — | — | Press release 2020 |
“—” = not publicly disclosed.
Governance Overview
| Attribute | Assessment |
|---|---|
Board size | 3 directors |
Independence | None demonstrably independent. Two are executives (and Remedent-linked, in De Vreese's case). The third is a co-founder through a management company. |
Committees | No audit, remuneration or nomination committees disclosed |
Chair/CEO separation | Formally yes (De Vreese chair, Verstraete CEO), but both are managing directors |
Statutory auditor | None appointed |
Governance code | None applicable or adopted on Euronext Access |
Related-party concentration | Shared address and executive with Remedent; incubation services from SmileWise (led by Shane De Vreese); Condor scanner (De Vreese-led company) in the protocol. The filings report "nihil" for related-party transactions outside normal market conditions. |
Board & Management Changes
| Date | Change | Source |
|---|---|---|
7 Mar 2018 | Dirk Verstraete becomes director / managing director. Gazette publication on 4 Apr 2018. | NBB FY2024; IR website |
29 Mar 2019 | Director resignation and appointment published alongside the capital increase. The Gazette title references both; names are not specified on the IR page. | IR website |
17 Oct 2022 | Philippe Van Acker leaves; the other three mandates are renewed | NBB FY2022 |
Major Shareholders
| Holder | Shares | Stake | As of | Source |
|---|---|---|---|---|
Remedent NV (99.99% owned by Remedent Inc., OTC: REMI) | 1,250,012 | c. 28.47% | 30 Sep 2020 | IR website |
Lausha NV (notified as senior executive / board member) | Net position not disclosed; transactions below | — | 2022–2023 | FSMA |
Free float (freely transferable at listing) | 1,533,400 | 74.8% of the 2.05m shares at the time | Apr 2018 | IR website |
Institutional holders | None disclosed | — | — | — |
Governance Detail
| Publication date | Notifier | Type | Quantity | Price (EUR) | Amount (EUR) |
|---|---|---|---|---|---|
16 Dec 2021 | Guy De Vreese | Purchase | 3,125 | 1.60 | 5,032.50 |
11 Feb 2022 | Guy De Vreese | Other (non-cash) | 79,341 | 0.00 | 0.00 |
4 Mar 2022 | Lausha NV | Purchase | 500 | 0.62 | 316.08 |
4 Mar 2022 | Lausha NV | Purchase | 600 | 0.80 | 489.18 |
31 Oct 2022 | Lausha NV | Purchase | 50 | 0.30 | 15.05 |
21 Jun 2023 | Lausha NV | Sale | 27,029 | 0.29 | 7,795.98 |
Competitive Landscape
Competitors by Segment
| Activity | Competitor | Country | Positioning vs MiB | Revenue | Source of identification |
|---|---|---|---|---|---|
Chiropractic chains (NL) | B.V. Chiropractie Rugcentra A.B. Van Beest D.C. | NL (Heerlen, Weert) | Established multi-site chiropractic group (10-company group per aggregator) | c. USD 1.23m for the Weert entity (aggregator estimate) | companydata.com |
Chiropractic chains (NL) | Chiropractie Centraal B.V. | NL | Direct chiropractic competitor | — | companydata.com |
Chiropractic (NL) | Path To Health Gorinchem B.V. | NL | Direct competitor | — | companydata.com |
Chiropractic (NL) | Rugcentrum Baarn B.V. | NL | "Back centre" positioning similar to Balans Rugcentrum | — | companydata.com |
Chiropractic (NL) | Gormley Chiropractie B.V.; Chiropractie Emmen B.V.; Chiropractie Harderwijk B.V. | NL | Regional chiropractic practices | — | companydata.com |
Physiotherapy (Eindhoven) | SGE (Stichting Gezondheidscentra Eindhoven) physiotherapy | NL | Large integrated primary-care network in MiB's home city | — | ZorgkaartNederland |
Physiotherapy (Eindhoven) | B-Fysic | NL | Multi-site physiotherapy group | — | ZorgkaartNederland |
Physiotherapy (Eindhoven) | Activum Fysiotherapie | NL | Multi-site physiotherapy | — | ZorgkaartNederland |
DNA lifestyle testing | Novogenia (Salzburg) | AT | Markets lifestyle DNA tests mainly via nutrition advisers, coaches and physiotherapists, the same B2B2C channel as DNA Talks | — | Lebensmittelpraxis (Oct 2024) |
DNA testing | 23andMe; iGENEA; ProGenom; Soledor | US / CH | Consumer and lifestyle genetic testing incumbents | — | Swissinfo |
Posture tech / wearables | Pao (Eindhoven); Think Healthy (US); Jenx (UK) | NL / US / UK | Named by CB Insights as comparables in posture care | — | CB Insights |
“—” = not publicly disclosed.
Peer Comparison FY2024
| Metric | MiB NV (parent) | Van Beest Rugcentra (Weert) |
|---|---|---|
Revenue | EUR 30,100 (FY2024) | c. USD 1.23m (aggregator, year n/d) |
Operating margin | n.m. (EBIT EUR 19,178 on non-recurring income) | — |
R&D intensity | "Minimal" | — |
“—” = not publicly disclosed.
Recent Developments
MiB has issued no press releases since 2 July 2020 (company press-release page).
Not identified in the period: * product launches, contract wins, leadership changes, guidance revisions, litigation, regulatory actions, layoffs or hiring announcements.



